SFM
CTOR

Spartan Fund Management’s Citius Oncology CTOR Stock Holding History

Spartan Fund Management’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-165,000
Closed -$1.83M – 102
2024
Q1 		$1.83M Buy
+165,000
New +$1.81M 3.73% 10

Other funds holding CTOR

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

Spartan Fund Management's CTOR Position: Q2 2024 in Review

Spartan Fund Management sold out of Citius Oncology (CTOR) in Q2 2024, closing a stake of 165,000 shares — an estimated $1.83M sold.

Spartan Fund Management first reported a position in CTOR in Q1 2024 and held it in 1 quarter. The position peaked at $1.83M in Q1 2024. 13 funds tracked by Wall St. Rank hold CTOR as of Q2 2024.

  • Spartan Fund Management reported no remaining Citius Oncology position as of Q2 2024 after selling out during the quarter.
  • Spartan Fund Management sold 165,000 Citius Oncology shares in Q2 2024, an estimated $1.83M.
  • Spartan Fund Management first reported a position in Citius Oncology in Q1 2024 and held it in 1 quarter.
  • Spartan Fund Management's Citius Oncology position peaked at $1.83M in Q1 2024.
  • 13 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2024.

Based on Spartan Fund Management's 13F filing for Q2 2024, filed 31 Jul 2024.